Want to see AU:LGP full AI Analyst Report?
Top Page
Little Green Pharma Ltd.
(Sydney:LGP)
Select Model
Select Model
Rating:46Neutral
Price Target:
AU$0.06
▼(-40.00% Downside)
Action:Reiterated
Date:10/02/26
The score is held back primarily by weak cash generation and inconsistent profitability, alongside a declining revenue year (financial performance). Technicals add further pressure with the price trading below major moving averages and only neutral momentum signals. Valuation is difficult to support with a negative P/E and no dividend yield data.
Positive Factors
Conservative balance sheet
Low leverage gives LGP greater financial flexibility than a heavily indebted business, helping it withstand operating volatility and preserve capacity for product development, market expansion, or other investment. Debt reduction versus earlier years further supports balance-sheet resilience.
Negative Factors
Recent revenue contraction
The latest revenue decline interrupts LGP’s longer-term scaling trajectory and indicates that recent demand, product mix, or market execution has not been consistently sustained. Continued contraction would reduce operating leverage and make it harder to absorb fixed business costs.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative balance sheet
Low leverage gives LGP greater financial flexibility than a heavily indebted business, helping it withstand operating volatility and preserve capacity for product development, market expansion, or other investment. Debt reduction versus earlier years further supports balance-sheet resilience.
Read all positive factors
Little Green Pharma Ltd. (LGP) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$53.82M
Dividend YieldN/A
Average Volume (3M)172.00K
Price to Earnings (P/E)―
Beta (1Y)0.49
Revenue Growth15.21%
EPS Growth-141.82%
CountryAU
Employees94
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)N/A
Shares Outstanding827,978,700
10 Day Avg. Volume171,934
30 Day Avg. Volume172,001
Financial Highlights & Ratios
PEG Ratio0.15
Price to Book (P/B)0.36
Price to Sales (P/S)0.70
P/FCF Ratio-37.45
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Little Green Pharma Ltd. Business Overview & Revenue Model
Company Description
Little Green Pharma Ltd, established in 2016 and based in West Perth, Australia, specializes in the worldwide cultivation, manufacturing, and distribution of medicinal cannabis products. Its extensive product range encompasses cannabis flower medi...
How the Company Makes Money
LGP makes money primarily by selling medicinal cannabis products that it cultivates and manufactures. Its core revenue stream is the supply of finished medicinal cannabis products (including cannabinoid-based formulations and flower products, wher...
Little Green Pharma Ltd. Financial Statement Overview
Summary
Income Statement
48
Neutral
Balance Sheet
74
Positive
Cash Flow
35
Negative
| Breakdown | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 42.42M | 36.82M | 25.63M | 19.86M | 14.04M |
| Gross Profit | 11.73M | 25.26M | 13.12M | 11.98M | 4.51M |
| EBITDA | 1.85M | -684.00K | -4.47M | -4.64M | -27.03M |
| Net Income | -1.41M | 3.32M | -8.15M | -9.21M | -24.07M |
Balance Sheet | |||||
| Total Assets | 93.75M | 96.12M | 86.29M | 98.62M | 95.95M |
| Cash, Cash Equivalents and Short-Term Investments | 1.42M | 2.38M | 4.97M | 12.40M | 20.09M |
| Total Debt | 4.69M | 4.67M | 5.14M | 11.87M | 15.87M |
| Total Liabilities | 10.72M | 11.11M | 10.21M | 16.39M | 20.47M |
| Stockholders Equity | 83.03M | 85.02M | 77.26M | 82.23M | 75.48M |
Cash Flow | |||||
| Free Cash Flow | -790.00K | -1.15M | -649.00K | -11.87M | -24.83M |
| Operating Cash Flow | 39.00K | -917.00K | 67.00K | -6.94M | -17.17M |
| Investing Cash Flow | -948.00K | -1.14M | -2.80M | -14.03M | -7.66M |
| Financing Cash Flow | 25.00K | -530.00K | -4.72M | 13.03M | 4.73M |
Little Green Pharma Ltd. Technical Analysis
Negative
0.10
Price Trends
0.07
Negative
0.07
Negative
0.09
Negative
Market Momentum
>-0.01
Positive
41.98
Neutral
<0.01
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:LGP, the sentiment is Negative. The current price of 0.1 is above the 20-day moving average (MA) of 0.07, above the 50-day MA of 0.07, and above the 200-day MA of 0.09, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 41.98 is Neutral, neither overbought nor oversold. The STOCH value of <0.01 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:LGP.
Little Green Pharma Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
53 Neutral | AU$8.30M | 0.33 | 64.70% | ― | -24.22% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | AU$53.82M | -13.26 | -1.67% | ― | 15.21% | -141.82% | |
46 Neutral | AU$11.27M | -2.39 | -9.80% | 10.53% | 5.74% | -222.22% | |
43 Neutral | AU$3.18M | -0.69 | -50.35% | ― | -4.87% | -9.78% | |
39 Underperform | AU$20.76M | -5.07 | 4388.00% | ― | -19.73% | 50.34% |
* Healthcare Sector Average
AU:LGP
Little Green Pharma Ltd.
0.06
-0.08
-56.43%
AU:EXL
Elixinol Wellness
0.02
<0.01
7.14%
AU:CAN
Cann Group
0.01
>-0.01
-28.57%
AU:PKP
Althea Group Holdings Ltd.
0.02
>-0.01
-10.53%
AU:VIT
Cronos Australia Ltd.
0.02
-0.05
-73.53%
Little Green Pharma Ltd. Corporate Events
Little Green Pharma appoints Pitcher Partners as new auditor after ASIC consent
Sep 29, 2026
Little Green Pharma Ltd has announced a change in its external auditor, marking a governance update for the newly merged LGP Cannatrek Group in the global medicinal cannabis sector. The Australian Securities and Investments Commission has consente...
Little Green Pharma appoints seasoned CFO to drive post-merger growth
Aug 20, 2026
Little Green Pharma Ltd has strengthened its executive team with the appointment of Jennifer Pilcher as Group Chief Financial Officer, effective 24 August 2026. Pilcher is a seasoned ASX executive with extensive finance, commercial and leadership ...
Little Green Pharma shareholders back strategy as merged cannabis group eyes European growth
Aug 13, 2026
Little Green Pharma Ltd, listed on the ASX as LGP, operates as a vertically integrated medicinal cannabis producer and distributor through the LGP Cannatrek Group, with substantial manufacturing and cultivation assets in Denmark and Australia and ...
Little Green Pharma Sets Out Vertically Integrated Medicinal Cannabis Ambitions
Aug 13, 2026
Little Green Pharma Ltd. used its AGM investor update to outline its strategy of building a premier global, vertically integrated medicinal cannabis group, leveraging Australian cultivation and targeting European markets. The release largely consi...
LGP Cannatrek Merger Builds Cash Position and Global Medicinal Cannabis Scale
Jul 30, 2026
Little Green Pharma’s merger with Cannatrek was completed on 1 June 2026, creating one of the world’s largest dedicated medicinal cannabis operators and reshaping its financial reporting structure. The newly formed LGP Cannatrek Group ...
Little Green Pharma Seeks ASX Quotation for 4 Million New Shares
Jul 27, 2026
Little Green Pharma Ltd has applied to the ASX for quotation of 4,000,000 new ordinary fully paid shares under its issuer code LGP, with an issue date of July 27, 2026. The additional quoted securities expand the company’s tradable share bas...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.